In addition, Hide et al. (2011) showed that the combination of a PTGS2 (COX2) inhibitor and an EGFR inhibitor prevented tumorgenesis of oligodendrocyte lineage-derived glioma-initiating cells. The gene discussed is PTGS2; the disease is central nervous system cancer.